tadalafil dosage - viagra - augmentin uses - http://sildenafilgeneric-citrate.com/ - levitra 20mg vs viagra 100mg - furosemide for dogs - lisinopril hctz - cialis generic - gabapentin 300mg - doxycycline hyclate 100mg

Latest News

CBS Consumer Products Shows Confidence in SPYR’s Pocket Starships with Licensing Deal for Star Trek IP

CBS Consumer Products Shows Confidence in SPYR’s Pocket Starships with Licensing Deal for Star Trek IP

Written by Ι Stock Market Media — June 14, 2017

SPYR, Inc. (OTCQB: SPYR) received what should be viewed as a vote of confidence from CBS Consumer Products in a recently announced licensing deal between the two companies. CBS is licensing its intellectual property (IP) from the long-running Star Trek television series: Star Trek: The Next Generation, Star Trek: Deep Space Nine and Star Trek: Voyager to SPYR, which can be taken as a vote of confidence by CBS Consumer Products in ...

Read More →
0

SPYR Inc.’s Future Just Got More Interesting with Hiring of Games Industry Rock Star

SPYR Inc.’s Future Just Got More Interesting with Hiring of Games Industry Rock Star

Written by Ι Stock Market Media — February 28, 2017

SPYR, Inc.’s (OTCQB: SPYR) investors should be growing more and more confident with the company as it is becomes more clear that 2017 could be the year that SPYR takes a giant leap forward in its evolution in the games industry. With its latest hire, SPYR should earn more credibility among industry leaders. Farshid Almassizadeh, who has joined SPYR as its Chief Strategic Advisor, is a 25-year veteran of the computer, video, and ...

Read More →
0

PharmaCyte Biotech Moves Closer to Filing IND with Naming of Comparator Arm for Upcoming Clinical Trial and Discusses Pivotal Trial Opportunity

PharmaCyte Biotech Moves Closer to Filing IND with Naming of Comparator Arm for Upcoming Clinical Trial and Discusses Pivotal Trial Opportunity

LAGUNA HILLS, Calif., Feb. 13, 2017 — PharmaCyte Biotech, Inc. (OTCQB:PMCB), a clinical stage biotechnology company focused on developing targeted treatments for cancer and diabetes using its signature live-cell encapsulation technology, Cell-in-a-Box®, today discussed the comparator arm for its upcoming clinical trial and provided additional clarification on its recent pre-IND meeting with the U.S. Food and Drug Administration (FDA) regarding its upcoming clinical trial in locally advanced, inoperable pancreatic cancer (LAPC).

In the company’s upcoming trial, the comparator arm that ...

Read More →
0

Facebook Adds SPYR’s Pocket Starships to New Gameroom Platform

Facebook Adds SPYR’s Pocket Starships to New Gameroom Platform

DENVER February 8, 2017 — SPYR, INC. (OTCQB: SPYR), a holding company with wholly owned subsidiaries in both the mobile game & app development and publishing industry, today announced that its flagship game, Pocket Starships, is among the first games that can be played in Facebook’s new Gameroom, now available in beta, for Windows PC gamers (https://www.facebook.com/gameroom).

Pocket Starships is a popular mobile game that is one of the few titles that offers real-time, cross platform play allowing both PC and ...

Read More →
0

SPYR Updates Shareholders on Plans and Objectives for 2017

SPYR Updates Shareholders on Plans and Objectives for 2017

DENVER, February 2017 — SPYR, INC. (OTCQB: SPYR), a holding company with wholly owned subsidiaries in both the mobile game & app development and publishing industry, and in the restaurant industry, today provides its shareholders with an update on its plans and objectives for the year 2017.

SPYR’s overarching goal for 2017 and beyond is to become a premier, diversified mobile games publisher, deriving revenue from games in various genres and appealing to multiple demographics.

Pocket Starships

SPYR’s main focus in 2016 ...

Read More →
0

PharmaCyte Biotech Secures Funding Opportunity for Pancreatic Cancer Clinical Trial

PharmaCyte Biotech Secures Funding Opportunity for Pancreatic Cancer Clinical Trial

Written by Ι Stock Market Media — December 12, 2016

All of the pieces are starting to fall into place for PharmaCyte Biotech (OTCQB: PMCB) and its upcoming human clinical trial in advanced pancreatic cancer. Just one week after the U.S. Food and Drug Administration (FDA) granted the biotech a pre-IND (Investigational New Drug) meeting to discuss the company’s clinical trial, PharmaCyte qualified to use its multi-million dollar “at-the-market” funding arrangement with Chardan Capital in order to enroll every single patient into its ...

Read More →
0
Page 1 of 30 12345...»
ContactUs.com ContactUs.com